Matthew Galsky

Matthew Galsky is a leading bladder and urothelial cancer researcher who has made important contributions to defining treatment algorithms for cisplatin-ineligible patients and developing immunotherapy approaches in bladder cancer. He led studies establishing atezolizumab and pembrolizumab as options for cisplatin-ineligible patients and has conducted extensive research into biomarkers of immunotherapy response in urothelial cancer. He co-chairs the Bladder Cancer Advocacy Network Scientific Advisory Board and leads major international trials. His work has directly shaped FDA approvals in urothelial cancer.